Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Sunshine Biopharma (SBFM) over the last 14 years, with Q3 2025 value amounting to -$770559.0.

  • Sunshine Biopharma's Net Cash Flow fell 95020.85% to -$770559.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.4 million, marking a year-over-year increase of 6457.11%. This contributed to the annual value of -$5.6 million for FY2024, which is 737.89% up from last year.
  • Per Sunshine Biopharma's latest filing, its Net Cash Flow stood at -$770559.0 for Q3 2025, which was down 95020.85% from $1.8 million recorded in Q2 2025.
  • Sunshine Biopharma's Net Cash Flow's 5-year high stood at $28.5 million during Q2 2022, with a 5-year trough of -$19.0 million in Q4 2022.
  • Moreover, its 5-year median value for Net Cash Flow was -$335777.0 (2021), whereas its average is $454076.6.
  • Per our database at Business Quant, Sunshine Biopharma's Net Cash Flow surged by 4195955.08% in 2022 and then tumbled by 2527025.18% in 2024.
  • Quarter analysis of 5 years shows Sunshine Biopharma's Net Cash Flow stood at -$335777.0 in 2021, then plummeted by 5547.28% to -$19.0 million in 2022, then skyrocketed by 84.23% to -$3.0 million in 2023, then skyrocketed by 36.95% to -$1.9 million in 2024, then soared by 59.12% to -$770559.0 in 2025.
  • Its Net Cash Flow was -$770559.0 in Q3 2025, compared to $1.8 million in Q2 2025 and -$1.6 million in Q1 2025.